Skip to main content
. 2017 May 23;7:2263. doi: 10.1038/s41598-017-02320-z

Figure 4.

Figure 4

RB1CC1, ATG12, MAP1LC3B expression in Kidney tissue at the end of the 12 weeks in the Control, Naive, Diabetes mellitus group, Diabetic nephropathy group, caffeic acid Prophylactic group, caffeic acid Treated group. (A) RB1CC1 mRNA; (B) ATG12 mRNA; (C) MAP1LC3B. Data are presented as fold change, where *indicates P < 0.05 compared to the control group (One way ANOVA followed by Bonferroni’s multiple comparison test), N = 8/group.